MK-3577

DB14957InvestigationalSmall molecule

MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).

Mechanism: Pharmacologically active on Glucagon receptor
Curator reviewed
Formula / weight: C₃₀H₃₀ClFN₂O₃ · 521.03 g/mol (avg)
Code names: MK-3577

Resolves to

Compound

UNII03TW1410NLCAS1019112-29-8ChEMBLCHEMBL1933350

Structure

InChIKeyFYRJJCYFYLLOSC-LXFBAYGMSA-NSMILESCCC[C@@H]([C@@H](C1=CNC2=C1C=C(C)C=C2F)C1=CC=C(Cl)C=C1)C1=CC=C(C=C1)C(=O)NCCC(O)=O

Targets

P47871GCGR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with MK-3577, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account